Issue link: http://viewer.e-digitaledition.com/i/90903
THAT'SNEWS New Medication Promising for Alzheimer's, Parkinson's and Multiple Sclerosis A NEW CLASS of drugs that reduce inflammation in the brain could eventually become a treatment option for chronic conditions such as Alzheimer's disease, Parkinson's disease and multiple sclerosis, and speed healing for patients with traumatic brain injuries. Under development at Northwestern University Feinberg School of Medicine, this class of medication would aim to prevent the formation of beta amyloid plaques in the brain, which are thought to lead to Alzheimer's disease. The drugs suppress brain inflammation and keep the brain from overproducing cytokine molecules. Currently known as MW151 and MW189, the drugs have already been put through the first phase 1 clinical trial stage. In a study conducted by Northwestern's Feinberg School MOUNTSINAI 11346_MD News_8.125x5.375_Layout 1 7/31/12 3:46 PM Page 1 and the University of Kentucky, mice that were given MW151 experienced a delay in the progression of Alzheimer's disease. s When your patients are dealing with cardiac issues, time is of the essence. At LI Heart, we make it a priority to provide the most technologically advanced and sophisticated methods of detecting cardiovascular disease, on site. Immediate appointments are always available. We find answers your patients need, all in one place. All the heart care accurately and quickly. Our board-certified cardiologists —led by Dr. Steven S. Shayani—are on the front lines of medical advancement. We provide the latest education on prevention and the newest and most effective treatment options. Our affiliation with The Mount Sinai Medical Center means that if intervention becomes necessary, access to one of the world's finest cardiac centers is a phone call away. This is the kind of cardiac care your patients deserve. 516-877-0977 |www.liheart.org MINEOLA • BELLMORE • GREAT NECK • KEW GARDENS • MANHASSET • WOODMERE AN AFFILIATE OF +++++++++++++++++++++++++++ +++++++++++++++++++++++++++ +++++++++++++++++++++++++++ +++++++++++++++++++++++++++ ++++++ ++++++ ++++++ ++++++ ++++++